跳至主要内容
临床试验/EUCTR2012-005076-34-BE
EUCTR2012-005076-34-BE进行中(未招募)1 期

Prolonged-release oral Fampridine in Multiple Sclerosis: effects on clinical, neurophysiological and quantified gait analysis parameters.A cross-over, double-blinded, placebo-controlled study.

Cliniques Universitaires Saint-Luc, Neurologie0 个研究点目标入组 24 人开始时间: 2012年12月14日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • To be eligible to participate in this study, candidates must meet the following eligibility criteria:
  • 1.aged > 18 years and < 65 years
  • 2.diagnosed with clinically definite MS (RR, SP or PP form)
  • 3.have an EDSS score = 6.0
  • 4.present a subjective complaint of impaired walking ability.
  • After 4 weeks of treatment, patients who respond to treatment with Fampridine (clinical response is based on improvement of walking ability and self assessed walking capacity) will be randomized into one of the groups (active drug or placebo)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 110
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Candidates will be excluded from study entry if any of the following exclusion criteria are met at the screening visit or at any time during the screening period:
  • 1.Presence of gait or walking disability not attributed to MS
  • 2.EDSS score > 6.0
  • 3.Relapse or steroid treatment within the last 4 weeks before inclusion
  • 4.Any history of seizure, epilepsy or other convulsive disorder with the exception of febrile seizures in childhood.
  • 5.Mild, moderate or severe renal impairment
  • 6.Contraindication to Motor Evoked Potentials
  • 7.Incapacity to walk on a treadmill at a comfortable speed during at least 3 minutes
  • 8.Concurrent treatment with other medicinal products containing 4-aminopyridine
  • 9.Concomitant use of medicinal products that are inhibitors of Organic Cation Transporter 2 (OCT2) for example, cimetidine.
  • 10.Breastfeeding or pregnant female subjects or subjects who are considering becoming pregnant.

研究者

发起方
Cliniques Universitaires Saint-Luc, Neurologie

相似试验

Prolonged-release oral Fampridine in Multiple... | 临床试验